

ACORDA THERAPEUTICS INC  
Form 8-K  
April 23, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **April 23, 2009**

**Acorda Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-50513**  
(Commission  
File Number)

**13-3831168**  
(I.R.S. Employer  
Identification No.)

**15 Skyline Drive, Hawthorne, NY**  
(Address of principal executive offices)

**10532**  
(Zip Code)

Registrant's telephone number, including area code: **(914) 347-4300**

**Not Applicable**

Former name or former address, if changed since last report

## Edgar Filing: ACORDA THERAPEUTICS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events**

On April 23, 2009, Acorda Therapeutics, Inc. (the Registrant ) issued a press release announcing that the Registrant had resubmitted its New Drug Application ( NDA ) for Fampridine-SR to the U.S. Food and Drug Administration (the FDA ). Fampridine-SR is a novel therapy being developed to improve walking ability in people with multiple sclerosis. The Registrant had previously received a Refuse to File letter (the RTF Letter ) on March 30, 2009, which cited the need to correct format issues and requested additional supporting information before the NDA could be accepted for review. Based on subsequent discussions with the FDA, the Registrant believes that all of the FDA s comments related to the RTF Letter have been addressed. A copy of the release is attached hereto as Exhibit 99.1 and incorporated by reference into this item.

**Item 9.01 Financial Statements and Exhibits**

99.1 Press Release dated April 23, 2009

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Acorda Therapeutics, Inc.

*April 23, 2009*

*By:*

*/s/ David Lawrence*

*Name: David Lawrence*

*Title: Chief Financial Officer*

Exhibit Index

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated April 23, 2009.

---